NEW YORK (360Dx) – VolitionRx on Tuesday announced a deal to evaluate and validate its technology and assist in the firm's efforts to secure large trials in cancer.
The three-year agreement is with Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich. VolitionRx CEO Cameron Reynolds said in a statement that Holdenrieder will support the company’s analytical and preanalytical research and assist in its trials aimed at lung, pancreatic, prostate, colorectal, breast, and ovarian cancer.
A company spokesperson added that Holdenrieder will help VolitionRx "in the external testing, evaluation, and validation of our Nu.Q assays." Also, the institute will support the firm establish and run its external quality assessment and control systems. "This will involve … assisting in within-run, between-run, and between laboratory evaluations of our assays."
Financial and other terms of the deal were not disclosed.